Navigation Links
Kosan Presents Preclinical Antitumor and Safety Data On,Next-Generation Epothilone KOS-1803 at AACR

HAYWARD, Calif., April 16, 2007 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated today presented preclinical data on KOS-1803, a next-generation epothilone, showing a high level of antitumor activity and a favorable pharmacokinetic and safety profile in a broad range of in vitro tests and in vivo cancer models. KOS-1803 has been chemically engineered to have a favorable tissue distribution pattern, which has been shown in models to result in excellent tumor penetration and a low side effect profile. In human tumor xenograft models, KOS-1803 has demonstrated antitumor activity in breast, lung, prostate and colorectal cancers, as well as in ovarian cancer and neuroblastoma where the extent and duration of tumor regression was curative. Kosan is currently advancing KOS-1803 through later-stage preclinical studies with the potential for future clinical development of the compound.

"KOS-1803 is an exciting, next-generation clinical candidate based on Kosan's proprietary epothilone D backbone that is demonstrating excellent potency and antitumor activity in multiple in vivo cancer models and in taxane-sensitive and resistant cancer cell lines," said Robert G. Johnson, Jr., M.D., Ph.D., Kosan's President and Chief Executive Officer. "KOS-1803 is particularly interesting due to its ability to induce tumor regression, activity at low doses, infrequent dosing schedule and attractive safety profile demonstrated in multiple xenograft models. Our development partner, Roche, and we expect that our lead epothilone compound, KOS-1584 (R1645), will enter Phase 2 trials in solid tumors later in 2007. KOS-1803 may represent a future opportunity to expand the therapeutic and commercial value of our companies' epothilone franchise."

Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement in the area of cancer. In early 2007, Roche and Kosan announced the decision to advance KOS-1584 into Phase 2 trials in solid tumors. The Phase 2 program is anticipated to begin in the second half of 2007.

Data on KOS-1803 were presented in a poster titled, "KOS-1803: A New, Rationally Designed Epothilone Analog with an Improved Pharmacological Profile and Efficacy in Xenograft Mouse Models," at the 2007 Annual Meeting of the American Association for Cancer Research (AACR), being held in Los Angeles, CA.

About Kosan

Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.

Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma in combination with Velcade(R) (bortezomib) and HER2-positive metastatic breast cancer in combination with Herceptin(R) (trastuzumab). In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.

Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-1584 (R1645) is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.

For additional information on Kosan Biosciences, please visit the company's website at www.kosan.com.

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of th e Private Securities Litigation Reform Act of 1995 (the "Act"). Such forward-looking statements include but are not limited to statements relating to the further development and potential safety and efficacy of KOS-1803 and KOS-1584; and initiations of clinical trials and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. There are a number of important factors that could cause the results of Kosan to differ materially from those indicated by these forward- looking statements, including, among others, risks related to the development of Kosan's product candidates, including the risk that studies may not demonstrate safety and efficacy sufficient to initiate clinical trials, continue clinical development, obtain the requisite regulatory approvals or to result in a marketable product; uncertainties with regards to the development activities that Roche will conduct or permit to be conducted for KOS-1803; and other risks detailed from time to time in the Company's SEC reports, including its Annual Report on Form 10-K for the year ended December 31, 2006 and other periodic filings with the SEC. Kosan does not undertake any obligation to update forward-looking statements.

Velcade(R) (bortezomib) is a registered trademark of Millennium Pharmaceuticals, Inc.

Herceptin(R) (trastuzumab) is a registered trademark of Genentech, Inc.

CONTACT: Jane Green, VP, Corporate Communications, +1-510-731-5335(office), or +1-415-652-4819 (mobile), or green@kosan.com

Web site: http://www.kosan.com/

Ticker Symbol: (NASDAQ-NMS:KOSN)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO
2. Kosan Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Epothilone KOS-1584 at ASCO
3. Kosan Presents Data on Lead Hsp90 Inhibitor, Tanespimycin, Showing Promising Antitumor Activity in Multiple Myeloma at ASCO
4. Kosan Presents Preliminary Phase 2 Data Showing Antitumor Activity of Hsp90 Inhibitor Tanespimycin in Metastatic Melanoma at ASCO
5. Kosan Presents Preclinical Data on Nuclear Export Inhibitors, Novel Anticancer Agents, at AACR
6. Kosan Presents Data on Cardiac Safety Profile of Hsp90 Inhibitor Tanespimycin (KOS-953) at AACR
7. Kosan Announces Data Presentations at Upcoming AACR Annual Meeting
8. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
9. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
10. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
11. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... 2016 Dehaier Medical Systems Ltd. (NASDAQ: ... markets and sells medical devices and wearable sleep respiratory ... strategic cooperation agreement with Hongyuan Supply Chain Management Co., ... June 20, 2016, to develop Dehaier,s new Internet medical ... Dehaier will leverage Hongyuan Supply Chain,s sales platform to ...
(Date:6/24/2016)... , June 24, 2016 Research ... World Market for Companion Diagnostic Tests" report to their ... Market for Companion Diagnostics The World Market ... and personalized medicine diagnostics. Market analysis in the report includes ... Test Market (In Vitro Diagnostic Kits) by Region (N. America, ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... A revolution ... the emergency ambulance transport experience for the millions of people who require these ... disrupted the taxi industry through the use of technology. Now, SmartEMS has put ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , ... Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , ... our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits ... terms of the latter, setting the bar too high can result in disappointment, perhaps ... slow progress toward their goal. , Research from PsychTests.com reveals that ...
Breaking Medicine News(10 mins):